The Technical Analyst
ImmuCell Corp [ICCC]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
ImmuCell Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.98% $5.16
America/New_York / 8 mai 2024 @ 11:50
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 39.99 mill |
| EPS: | -0.750 |
| P/E: | -6.88 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 7.75 mill |
| Avg Daily Volume: | 0.0080 mill |
| RATING 2024-05-07 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -6.88 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.17x |
| Company: PE -6.88 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 4.99 - 5.33 ( +/- 3.28%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-09-06 | Tomsche David Scott | Buy | 3 100 | Common stock $0.10 per value per share |
| 2023-06-28 | Gathagan Bryan K. | Buy | 15 000 | Non-Qualified Stock Options (Right to buy) |
| 2023-06-16 | Gathagan Bryan K. | Buy | 0 | |
| 2023-03-14 | Tomsche David Scott | Buy | 100 | Common Stock, $0.10 per value per share |
| 2023-03-14 | Tomsche David Scott | Buy | 69 | Common Stock, $0.10 per value per share |
| INSIDER POWER |
|---|
| 100.00 |
| Last 96 transactions |
| Buy: 315 997 | Sell: 92 686 |
Forecast:
13:29 - $5.11
Live Trading Signals (every 1 min)
Forecast
1: 11:59 - $5.16
Forecast 2: 12:49 - $5.11
Forecast 3: 13:29 - $5.11
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $5.16 (0.98% ) |
| Volume | 0.0028 mill |
| Avg. Vol. | 0.0080 mill |
| % of Avg. Vol | 35.00 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ICCC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ICCC
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Latest Press Releases
2024-04-09 16:05:00 - Press Release
Immucell Announces Preliminary, Unaudited Sales Results for Q1 2024
Portland, maine, april 09, 2024 (globe newswire) -- immucell corporation (nasdaq: iccc) (“immucell” or the “company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the first quarter of 2024, which ended march 31, 2024.
2024-02-27 16:05:00 - Press Release
Immucell Announces Unaudited Financial Results For the Quarter And Year Ended December 31, 2023
Portland, maine, feb. 27, 2024 (globe newswire) -- immucell corporation (nasdaq: iccc) (“immucell” or the “company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter and year ended december 31, 2023.
2024-02-16 09:30:00 - Press Release
Immucell To Announce Unaudited Financial Results For The Quarter And Year Ended December 31, 2023
Conference call scheduled for wednesday, february 28, 2024 at 9:00 am et conference call scheduled for wednesday, february 28, 2024 at 9:00 am et
2024-01-08 16:05:00 - Press Release
Immucell Announces Preliminary, Unaudited Sales Results For Q4 2023
Portland, maine, jan. 08, 2024 (globe newswire) -- immucell corporation (nasdaq: iccc) (“immucell” or the “company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the fourth quarter of 2023, which ended december 31, 2023.
2023-11-13 16:05:00 - Press Release
Immucell Announces Unaudited Financial Results For the Quarter Ended September 30, 2023
Portland, maine, nov. 13, 2023 (globe newswire) -- immucell corporation (nasdaq: iccc) (“immucell” or the “company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended september 30, 2023.
Latest News
2024-02-16 09:30:00 - GlobeNewsWire
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023
Conference Call Scheduled for Wednesday, February 28, 2024 at 9:00 AM ET Conference Call Scheduled for Wednesday, February 28, 2024 at 9:00 AM ET
2023-11-07 12:15:00 - GlobeNewsWire
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023
Conference Call Scheduled for Tuesday, November 14, 2023 at 9:00 AM ET Conference Call Scheduled for Tuesday, November 14, 2023 at 9:00 AM ET
2023-08-07 12:00:00 - GlobeNewsWire
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023
PORTLAND, Maine, Aug. 07, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended June 30, 2023 after the market closes on Thursday, August 10, 2023. The Company has scheduled a conference call the next morning, Friday, August 11, 2023, at 9:00 AM ET to review its second quarter financial results.
2023-05-12 10:00:10 - Seeking Alpha
ImmuCell Corporation (ICCC) Q1 2023 Earnings Call Transcript
ImmuCell Corporation (NASDAQ:ICCC ) Q1 2023 Earnings Conference Call May 12, 2023 9:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Michael Brigham - President and CEO Conference Call Participants Operator Good morning, and welcome to ImmuCell Corporation Reports First Quarter 2023 Unaudited Financial Results Conference Call. All participants will be in a listen-only mode.
2023-05-04 06:30:00 - GlobeNewsWire
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2023
PORTLAND, Maine, May 04, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2023 after the market closes on Thursday, May 11, 2023. The Company has scheduled a conference call the next morning, Friday, May 12, 2023, at 9:00 AM ET to review its first quarter financial results.
2023-02-22 12:50:34 - Seeking Alpha
ImmuCell Corporation (ICCC) Q4 2022 Earnings Call Transcript
ImmuCell Corporation (NASDAQ:ICCC ) Q4 2022 Earnings Conference Call February 22, 2023 9:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Michael Brigham - President and CEO Conference Call Participants Operator Good morning, and welcome to ImmuCell Corporation Reports Fiscal Year 2022 Unaudited Financial Results Conference Call. All participants will be in a listen-only mode.
2023-02-15 11:55:00 - GlobeNewsWire
ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2022
Conference Call Scheduled for Wednesday, February 22, 2023 at 9:00 AM ET Conference Call Scheduled for Wednesday, February 22, 2023 at 9:00 AM ET
2022-11-22 11:37:06 - Seeking Alpha
ImmuCell Corporation (ICCC) Q3 2022 Earnings Call Transcript
ImmuCell Corporation (NASDAQ:ICCC ) Q3 2022 Earnings Conference Call November 22, 2022 9:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Michael Brigham - President and CEO Bobbi Jo Brockmann - Vice President, Sales and Marketing Conference Call Participants Jim Barrett - Barrett Investments Operator Good morning. And welcome to ImmuCell Corporation Reports Third Quarter Fiscal Year 2022 Financial Results Conference Call.
2022-09-14 17:00:00 - GlobeNewsWire
ImmuCell to Participate in the Lytham Partners Fall 2022 Investor Conference
PORTLAND, Maine, Sept. 14, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, announced today it will participate in the Lytham Partners Fall 2022 Investor Conference taking place virtually on September 28-29, 2022.
2022-08-12 13:13:18 - Seeking Alpha
ImmuCell Corporation (ICCC) CEO Michael Brigham on Q2 2022 Results - Earnings Call Transcript
ImmuCell Corporation (NASDAQ:ICCC ) Q2 2022 Earnings Conference Call August 12, 2022 9:00 AM ET Company Participants Joe Diaz - Investor Relations Michael Brigham - President and Chief Executive Officer Conference Call Participants George Melas - MKH Management Operator Good morning. This is Anthony from Chorus Call and I will be assisting with our conference call this morning.